78 related articles for article (PubMed ID: 2864283)
1. [Behavior disorder in rats induced by Madopar and its pharmacological correction].
Bondarenko NA; Bondarenko NA
Farmakol Toksikol; 1985; 48(4):31-4. PubMed ID: 2864283
[TBL] [Abstract][Full Text] [Related]
2. [THe selective effect of neuroleptics on a dopamine-dependent behavioral disorder in rats in the extrapolation escape test].
Bondarenko NA
Biull Eksp Biol Med; 1990 Nov; 110(11):506-8. PubMed ID: 1982079
[TBL] [Abstract][Full Text] [Related]
3. [Effect of L-dihydroxyphenylalanine on rat behavior and on catecholamine metabolism of the brain in rats with different degrees of emotional-behavioral reactivity].
Bondarenko NA; Miroshnichenko II; Kudrin VS; Bondarenko NA
Biull Eksp Biol Med; 1988 Aug; 106(8):168-70. PubMed ID: 3416051
[TBL] [Abstract][Full Text] [Related]
4. [Behavioral assessment of neuroleptics (2)--stereotypy].
Koshikawa N
Yakubutsu Seishin Kodo; 1992 Feb; 12(1):1-7. PubMed ID: 1357840
[TBL] [Abstract][Full Text] [Related]
5. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic aspects of some behavioral effects of psychotropic drugs.
Melzacka M
Pol J Pharmacol Pharm; 1984; 36(2-3):117-36. PubMed ID: 6147827
[TBL] [Abstract][Full Text] [Related]
7. 3-O-methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse.
Himori N; Tanaka Y; Kurasawa M; Mishima K; Akaike N
Pharmacology; 1994 Apr; 48(4):226-33. PubMed ID: 8177909
[TBL] [Abstract][Full Text] [Related]
8. Psychopharmacological profile of mesterolone.
Baran L; Przegaliński E
Pol J Pharmacol Pharm; 1981 Oct; 33(3):299-303. PubMed ID: 7198778
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study of the psychotropic activity of tuftsin and its analogs].
Val'dman AV; Bondarenko NA; Kozlovskaia MM; Rusakov DIu; Kalikhevich VN
Biull Eksp Biol Med; 1982 Apr; 93(4):49-52. PubMed ID: 6896289
[TBL] [Abstract][Full Text] [Related]
10. Effect of muscarinic receptor agonists on animal models of psychosis.
Karan RS; Ravishankar P; Pandhi P
Methods Find Exp Clin Pharmacol; 2000 Apr; 22(3):169-72. PubMed ID: 10893700
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
[TBL] [Abstract][Full Text] [Related]
13. Experimental evaluation of the possible neuroleptic activity of clomipramine.
Balsara JJ; Chandorkar AG
Indian J Physiol Pharmacol; 1978; 22(3):263-9. PubMed ID: 31334
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa.
Eltayb A; Wadenberg ML; Svensson TH
Biol Psychiatry; 2005 Aug; 58(4):337-43. PubMed ID: 16102547
[TBL] [Abstract][Full Text] [Related]
15. [Model of the defense reaction in rats to study the antifenamine effect of neuroleptics for demonstrating their specific action].
Baturin VA; Iuntsev SV
Farmakol Toksikol; 1984; 47(5):110-3. PubMed ID: 6149952
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).
Zhang TT; Song M; Hang TJ; Xu XF; Wen AD; Yang L; Jia L
J Clin Pharm Ther; 2009 Jun; 34(3):345-54. PubMed ID: 19646081
[TBL] [Abstract][Full Text] [Related]
17. Effects of antihistaminic drugs in tests for antidepressant action.
Rogóz Z; Skuza G; Sowińska H
Pol J Pharmacol Pharm; 1981 Oct; 33(3):321-35. PubMed ID: 6119682
[TBL] [Abstract][Full Text] [Related]
18. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
[TBL] [Abstract][Full Text] [Related]
19. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity.
Becker A; Grecksch G
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1267-77. PubMed ID: 15588753
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological evaluation of 2-(4-methylaminobutoxy)diphenylmethane hydrochloride (MCI-2016), a new psychotropic drug with antidepressant activity.
Tobe A; Yoshida Y; Ikoma H; Tonomura S; Kikumoto R
Arzneimittelforschung; 1981; 31(8):1278-85. PubMed ID: 7197535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
